Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06247904

NIBS Therapy in Subacute Spinal Cord Injury

No accepted clinical therapies exist for repair of motor pathways following spinal cord injury (SCI) in humans, leaving permanent disability and devastating personal and socioeconomic cost. A robust neural repair strategy has been demonstrated in preclinical studies, that is ready for translation to recovery of hand and arm function in human SCI, comprising daily transcranial magnetic stimulation treatment at the inpatient rehabilitation facility. This study will establish clinical effect size of the intervention, as well as safety and feasibility necessary for a subsequent controlled efficacy trial and inform preclinical studies for dosing optimization.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Jefferson Moss-Magee Rehabilitation - Elkins Park

Elkins Park, Pennsylvania, 19027, United States

About this study

The objective of this proposal is to begin translating findings from pre-clinical studies to human motor deficits following cervical SCI (cervSCI). This HF-rTMS treatment protocol has not been previously assessed in human SCI and is qualitatively different from rTMS protocols reported to transiently modulate excitability of existing pathways, previously demonstrated in the literature. The protocol involves a daily stimulation of ~10 mins bilateral HF-rTMS for 2 weeks. SCI participants will be studied in a United States inpatient setting for this phase I study.

Given the findings in the pre-clinical model of robust axonal sprouting and functional synapse formation close to the damaged tissue using the above stimulation parameters, the transcranial magnetic stimulation treatment will target the hand-forearm region of the primary motor cortex, bilaterally. The aim is to include the cortical representation of affected muscles adjacent to the neurological level of injury. This zone often contains a mix of clinically and neurophysiologically intact, weakly innervated and denervated corticospinal pathways. Under standard sub-acute rehabilitation care, recovery of up to 1 neurological level of injury (NLI) is often the case, but improvement of 2 or more levels is far less common (<30% of patients). To examine the feasibility and safety of this novel intervention is the principal aim of the study. The associated potential clinical and neurophysiological changes will also be evaluated. These preliminary data will be used to power a subsequent efficacy trial to test the hypothesis that rTMS induced corticospinal augmentation will result in greater than typical extension of the NLI in human SCI, assessed up to the stable recovery phase at 6 months post-injury.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Post traumatic or non-traumatic cervical spinal cord injury (SCI) with residual upper-extremity paralysis
  • Time post-injury less than six weeks
  • Neurological Level of Injury (NLI) C4-C6
  • ASIA Impairment Scale (AIS) A-D
  • Sensory and motor zone of partial preservation (ZPP, clinically complete or incomplete)
  • Age 18 to 80 years old

Exclusion criteria

  • Ventilator dependence;
  • Concurrent neurological condition affecting sensory or motor pathways or otherwise limiting ability to participate in the study;
  • Evidence of trauma-related brain injury;
  • Contraindications for TMS or history of seizure or seizure risk;
  • Spinal instability;
  • Uncontrolled autonomic dysreflexia;
  • Severe muscular or skeletal or neuropathic pain;
  • Known or suspected pregnancy;
  • Medically unstable or any reason the physician may deem as inappropriate for the participant to enroll or continue in the study.

Treatment and study plan

Active rTMS

Device

The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be determined from individual MRI-modeled e-field, to achieve approximately motor threshold in the target area.

Other names: active repetitive transcranial magnetic stimulation

sham rTMS

Device

The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be close to zero (negligible) since sham coil will be used for the intervention

Other names: sham repetitive transcranial magnetic stimulation

Primary outcomes

  1. Eligibility - (Percentage candidates eligible of screened patients)

    Time frame: 21 months (Recruitment period)

    The proportion of patients who can take part in the study, whether they later agree to or not.

  2. Recruitment - (Percentage candidates enrolled of approached patients)

    Time frame: 21 months (Recruitment period)

    The proportion of eligible patients who agree to take part in the study.

  3. Adherence to intervention - (Percentage candidates who dropout during the intervention period of enrolled candidates)

    Time frame: 2 years (Duration of human subjects' involvement)

    Proportion of intervention-related dropouts.

  4. Adherence to outcome assessment - (Percentage candidates who do not complete outcome assessments of enrolled candidates)

    Time frame: 2 years (Duration of human subjects' involvement)

    Proportion of patients that complete the assessments at the start and the end of the intervention.

  5. Retention - (Percentage candidates who do not complete 6-month follow up of enrolled candidates)

    Time frame: 2 years (Duration of human subjects' involvement)

    The number of patients who drop out or were 'lost' at the 6-month follow-up.

  6. Adverse Events

    Time frame: 2 years (Duration of human subjects' involvement)

    Rate of adverse and serious adverse events

Secondary outcomes

  1. Motor neurological level change (ISNCSCI assessment)

    Time frame: Baseline and 6 months after injury

    Proportion of patients with Improvement of 2 or more motor zone of partial preservation levels from baseline to 6 months after injury.

  2. Incidence of reconnectivity (Proportion: MEP absent, covert to MEP present)

    Time frame: Baseline and 6 months after injury

    The proportion of re-connectivity will be estimated by treatment group.

  3. Change in motor threshold between groups (Difference in %Maximum Stimulator Output to achieve motor threshold)

    Time frame: Baseline and 6 months after injury

    Change in motor threshold of key muscles will be estimated bilaterally within each group and a comparison of the change between groups.

Sponsors and collaborators

Lead sponsor

Albert Einstein Healthcare Network

Other

Collaborators

  • Burke Medical Research Institute
  • Massachusetts General Hospital
  • Pennsylvania Department of Health
  • University of Mississippi Medical Center
  • University of Sao Paulo
  • Weill Medical College of Cornell University

Registry information

Official study title

Noninvasive Brain Stimulation Therapy in Subacute Human Spinal Cord Injury: A Translational Study

Acronym: NIBS-SCI1

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Feb 8, 2024
Registry last updated
Apr 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.